Coral Gables, United States
Relmada Therapeutics, Inc is a clinical-stage company with a focus on developing innovative therapies for diseases of the central nervous system (CNS), particularly major depressive disorder (MDD). Their lead program, REL-1017, a novel NMDA receptor channel blocker, is currently in late-stage development for the treatment of MDD in adjunctive and monotherapy Phase 3 studies. The ongoing RELIANCE Phase 3 Clinical Research Program aims to evaluate the potential for REL-1017 as a rapid-acting, oral, once-daily antidepressant treatment. Notably, in a Phase 2 trial, REL-1017 demonstrated rapid, robust, and sustained antidepressant effects with statistically significant improvements compared to placebo.
Additionally, the company is advancing a clinical-stage program in neurodegenerative diseases based on psilocybin and select derivative molecules. Relmada Therapeutics was founded in 2004 and operates within the Biotechnology and Pharmaceutical industries.
The company's recent Post-IPO Equity investment at 08 December 2021 underscores investor interest in their work. As they traverse the realms of CNS disease treatment, Relmada continues to showcase promising developments and a strong commitment to enhancing patient well-being.
For media inquiries, please contact [email protected].
